Search

Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management

Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management. Click here to find out more information.

COVID-19 Joining forces against COVID-19

While the challenges posed by the COVID-19 pandemic are massive, so are the good examples of corporate citizenship arising all over the world. Learn more.

Boehringer Ingelheim India and Vvaan Lifesciences Pvt Ltd announce strategic distribution partnership to expand pet portfolio reach.

One step further in fighting rabies in Vietnam

A expedition team set off to the Duc Hue District. The purpose? To vaccinate the entire dog and cat population of several villages. Find out more.ral villages.

More Potential

Continuing a journey that began more than 135 years ago, Boehringer Ingelheim steps up its commitment to sustainable development. Find out more here.

COVID-19 Boehringer Ingelheim Thailand equips frontline

Boehringer Ingelheim Thailand is working together with the Thai Department of Disease Control during the pandemic. Click here to learn more.

It is about saving lives Alexis Jaliquias feline blood bank

Veterinarian Alexis Jaliquias founded one of the first blood banks for cats in South America. Click here to read about this story and find out more.

Boehringer Ingelheim & Fighting COVID-19 | Boehringer Ingelheim

Learn how Boehringer Ingelheim may not develop human vaccines but is still part of the medical research collective helping to fight this pandemic.

pet care digital age

Pets can be family members, trusted companions – and they are also part of a large global industry. Learn more about pet care in the digital age here.

Watch out: the tick season is there!

From a Southern tick species spreading throughout Europe to the fact American pop singer Justin Bieber is battling Lyme disease, ticks are in the news.

Pet industry trends Millennials

Millennials are now shaping pet markets and facing new issues in pet healthcare. Click here to read and learn more about this new generation of pet owners.

Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug

Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug.

Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India

Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India. Click here to find out and learn more.

EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalization for heart-failure and cardiovascular death

EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalisation for heart-failure and cardiovascular death. Find out more here.

Boehringer Ingelheim India’s stroke awareness campaign enters the GUINNESS WORLD RECORDS™

Boehringer Ingelheim India’s stroke awareness campaign enters the GUINNESS WORLD RECORDS™. Click here to read the press release and find out more.

Boehringer Ingelheim India signs MoU with the Government of Maharashtra, to strengthen stroke care in the state

We are independent, family-owned

At Boehringer Ingelheim we are independent, family-owned and intend to remain so. Click here to discover how we live our Leitbild and learn more.

Boehringer Ingelheim introduces NexGard SPECTRA® for dogs in India

Boehringer Ingelheim India recognized as Top Employer 2024

Boehringer Ingelheim and IIT Kanpur join hands for social impact

Boehringer Ingelheim India to support Lenek Technologies, a startup incubated at SIIC, IIT Kanpur to improve tuberculosis screening through its innovative handheld X-ray device.

COVID-19 Pandemic support in Vietnam

Find out how Boehringer Ingelheim Vietnam is joining hands with the government and hospitals. Click here to find out and learn more information.

Our Ambition 2025

Boehringer Ingelheim’s commitment to serve humankind can be met if we are the preferred partner and admired competitor in three areas. Learn more here.

Interview: Excellence in stem cell treatments

Acquisition of GST reflects the enormous potential of biotechnology research to provide breakthrough therapies for major diseases. Learn more.

The Core of our Leitbild

Click here to find out about the core of our leitbild. Here you can find out information about who we are and what we strive for at Boehringer Ingelheim.

Women in STEM 2022

Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM. Click here to find out more.

About Us

Human Health

Animal Health